Thursday, November 21, 2013
This week in therapeutics
Publication and contact
III synthase (UROS)
Mouse and cell culture
studies suggest proteasome inhibitors could be useful for treating congenital
erythropoietic porphyria, which is caused by destabilizing mutations in UROS.
In human erythrocyte cell lines carrying mutations in UROS that
destabilize the protein, the proteasome inhibitor Velcade
partially protected the synthase from premature degradation. In mice carrying
analogous Uros mutations, Velcade decreased disease severity compared
with saline. Next steps could include evaluating other proteasome inhibitors
in the preclinical models and testing various dosing protocols.
Pharmaceutical Co. Ltd. and Johnson
& Johnson market Velcade to treat multiple myeloma (MM)
and mantle cell lymphoma (MCL).
Amgen Inc. and Ono
Pharmaceutical Co. Ltd. market the selective proteasome
to treat MM.
At least 10 companies have proteasome inhibitors in Phase III testing or
earlier to treat various cancers.
SciBX 6(45); doi:10.1038/scibx.2013.1292
Published online Nov. 21, 2013
Patent and licensing status
J.-M. et al. Proc. Natl. Acad. Sci. USA; published online Oct. 21,
Contact: Emmanuel Richard, University of Bordeaux Segalen, Bordeaux,
All contents Copyright © 1993-2017 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]